<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005004</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N01-PMD</org_study_id>
    <nct_id>NCT01005004</nct_id>
  </id_info>
  <brief_title>Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects</brief_title>
  <official_title>Phase I Study of the Safety and Preliminary Efficacy of Intracerebral Transplantation of HuCNS-SC® Cells for Connatal Pelizaeus-Merzbacher Disease (PMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>StemCells, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>StemCells, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and preliminary effectiveness of human
      central nervous system stem cells (HuCNS-SC®) transplantation in patients with Connatal
      Pelizaeus-Merzbacher Disease (PMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled subjects will be transplanted with HuCNS-SC cells into the brain and will receive
      immunosuppression for nine months. The study observation period is for one year after
      transplant surgery. Thereafter, subjects will be enrolled in a long-term observational
      follow-up study for four years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment through clinical neurological and MRI evaluation.</measure>
    <time_frame>one year post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI examination for post-transplant myelination</measure>
    <time_frame>one year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Pelizaeus-Merzbacher Disease</condition>
  <arm_group>
    <arm_group_label>HuCNS-SC cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracerebral implantation of HuCNS-SC via direct injection during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HuCNS-SC cells</intervention_name>
    <description>intracerebral transplantation</description>
    <arm_group_label>HuCNS-SC cells</arm_group_label>
    <other_name>Human central nervous system stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed clinical diagnosis of connatal PMD

          -  Molecular genetic confirmation of mutation in the proteolipid protein 1 (PLP1) gene

          -  MRI consistent with PMD as interpreted by a qualified neuroradiologist

        Exclusion Criteria:

          -  Other significant congenital brain abnormality not related to PMD

          -  Previous participation in gene transfer or cell transplant trial

          -  Presence of neurological signs and symptoms not consistent with PMD

          -  Current or prior malignancy

          -  Prior organ, tissue or bone marrow transplant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Huhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>StemCells, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMD</keyword>
  <keyword>stem cells</keyword>
  <keyword>Pelizaeus-Merzbacher Disease</keyword>
  <keyword>human stem cells</keyword>
  <keyword>central nervous system stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

